Relatlimab, the first commercially developed anti-LAG-3 mAb, was entered into clinical trials in 2013, and it received FDA approval in March 2022, along with the PD-1 inhibitor nivolumab in the combination treatment Opdualag (Bristol Myers Squibb), which is used for the treatment of unresectable or metastatic melanoma. Here, LAG3 is linked to metastatic melanoma.